Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis.
The relationship between hemodialysis (HD) symptoms and dialyzer membrane composition and area, blood-flow, treatment duration, urea removal, ultrafiltration volume, leukocyte activation, and complement generation (C3a) was studied in 20 patients undergoing 234 HD treatments by 12 different modes in random order using Cuprophan, hemophane, or polyamide membranes with small or large membrane areas with high Qb (400 ml/min) and short duration (2 h) or low Qb (200 ml/min) and long duration (4 h). Fewer symptoms occurred during the 2-h HD at high Qb than during the 4-h HD with low Qb (19% vs. 32%, p = 0.0351). No differences were observed between different dialyzer membranes or areas. More intradialytic symptoms occurred when urea elimination was high than it was low (p = 0.0044). Leukocyte activation (leukocyte drop) after 15 min of dialysis and complement generation did not influence symptom incidence. Blood pressure changes were mainly influenced by ultrafiltration volume (p < 0.001). Symptoms between dialyses were determined by urea removal and ultrafiltration. Membrane, area, or Qb were of no importance. Thus, duration of dialysis, urea removal, and demand for ultrafiltration, but not membrane composition, area, or biocompatability, are important for the development of HD-related symptoms.
Skroeder
N R
NR
Department of Medicine, Karolinska Hospital, Stockholm, Sweden.
Jacobson
S H
SH
Lins
L E
LE
Kjellstrand
C M
CM
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001672:Biocompatible Materials; D001794:Blood Pressure / Q000502:physiology; D015926:Complement C3a / Q000096:biosynthesis; D004867:Equipment Design; D005260:Female; D006261:Headache / Q000209:etiology; D018056:Hemorheology; D006801:Humans; D007022:Hypotension / Q000209:etiology; D007962:Leukocytes / Q000502:physiology; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects* / Q000295:instrumentation / Q000379:methods*; D013499:Surface Properties; D013997:Time Factors; D014462:Ultrafiltration; D014508:Urea / Q000097:blood
D001672:Biocompatible Materials; D008567:Membranes, Artificial; D015926:Complement C3a; D014508:Urea